Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update.
Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Frere, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Baudoux, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire
Schaaf-Lafontaine, Nicole ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update.
Baron F, Siquet J, Schaaf-Lafontaine N, Baudoux E, Hermanne JP, Fillet G, et al. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. Haematologica 2002;87:78-88.
Baron F, Baudoux E, Frere P, Tourqui S, Schaaf-Lafontaine N, Greimers R, et al. Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells. J Hematother Stem Cell Res 2002; 11:301-14.
Baron F, Frere P, Baudoux E, Sautois B, Fillet G, Beguin Y. Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. Haematologica 2003;88:478-80.
McSweeney PA, Niederwieser D, Shizuru J, Sandmaier BM, Molina A, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;101:1620-9.
Schetelig J, Kroger N, Held TK, Thiede C, Krusch A, Zabelina T, et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft- versus-host disease. Haematologica 2002;87:299-305.
Baron F, Beguin Y. Nonmyeloablative allogeneic hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002;11:243-63.
Kobbe G, Schneider P, Aivado M, Zohren F, Schubert D, Fenk R, et al. Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. Exp Hematol 2002;30:1346-53.
Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Champlin R. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994;57:82-7.
